Menu Search
Equities

Cryofocus Medtech Shanghai Co Ltd

6922:HKG.HZ

Cryofocus Medtech Shanghai Co Ltd

Actions
  • Price (HKD)7.55
  • Today's Change-0.01 / -0.13%
  • Shares traded13.00k
  • 1 Year change-54.52%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 08:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Cryofocus Medtech Shanghai Co Ltd grew revenues 50.83% from 27.15m to 40.95m while net income improved from a loss of 112.22m to a smaller loss of 97.49m.
Gross margin76.35%
Net profit margin-275.28%
Operating margin-273.46%
Return on assets-51.79%
Return on equity-65.74%
Return on investment-66.30%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Cryofocus Medtech Shanghai Co Ltd fell by 123.02m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 95.89m for operations while cash used for investing totalled 15.10m.
Cash flow per share-0.4764
Price/Cash flow per share--
Book value per share0.5422
Tangible book value per share0.5422
More ▼

Balance sheet in CNYView more

Cryofocus Medtech Shanghai Co Ltd appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio2.53
Quick ratio2.06
Total debt/total equity0.32
Total debt/total capital0.2303
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.